{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:45:40Z","timestamp":1774867540071,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s10354-006-0335-0","type":"journal-article","created":{"date-parts":[[2006,10,17]],"date-time":"2006-10-17T19:36:11Z","timestamp":1161113771000},"page":"501-507","source":"Crossref","is-referenced-by-count":1,"title":["Topical Drug Therapy in Glaucoma","Die topische Pharmakotherapie des Glaukoms"],"prefix":"10.1007","volume":"156","author":[{"given":"Hemma","family":"Resch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Garhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"335_CR1","unstructured":"World health organization (1997) Blindness and visual disability. Part II of VII: major causes worldwide. Fact sheet N143. Available: http:\/\/www.who.org (accessed 2002 Aug 26)"},{"key":"335_CR2","volume-title":"Preferred Practice Patterns: primary open-angle glaucoma","author":"Glaucoma Panel, Preferred Practice Patterns Committee, American Academy of Ophthalmology","year":"1996","unstructured":"Glaucoma Panel, Preferred Practice Patterns Committee, American Academy of Ophthalmology (1996) Preferred Practice Patterns: primary open-angle glaucoma. San Francisco (CA): The Academy"},{"key":"335_CR3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archopht.1977.04450040071009","volume":"95","author":"TJ Zimmerman","year":"1977","unstructured":"Zimmerman TJ, Kaufman HE (1977) Timolol, dose response and duration of action. Arch Ophthalmol 95: 605\u2013607","journal-title":"Arch Ophthalmol"},{"key":"335_CR4","first-page":"153","volume":"5","author":"D Spinelli","year":"1982","unstructured":"Spinelli D, Montanari P, Vigasio F, Cormanni V (1982) Effects of timolol maleate on untreated contralateral eyes. J Fr Ophtalmol 5: 153\u2013158","journal-title":"J Fr Ophtalmol"},{"key":"335_CR5","first-page":"1239","volume":"11","author":"WP Boger 3rd","year":"1979","unstructured":"Boger WP 3rd (1979) Timolol: short term \"escape\" and long term \"drift\". Ann Ophthalmol 11: 1239\u20131242","journal-title":"Ann Ophthalmol"},{"key":"335_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0161-6420(78)35673-6","volume":"85","author":"WP Boger 3rd","year":"1978","unstructured":"Boger WP 3rd, Puliafito CA, Steinert RF, Langston DP (1978) Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 85: 259\u2013267","journal-title":"Ophthalmology"},{"key":"335_CR7","first-page":"485","volume":"10","author":"FC Hugues","year":"1987","unstructured":"Hugues FC, Le Jeunne C, Munera Y, Dufier JL (1987) Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics. Fr Ophtalmol 10: 485\u2013490","journal-title":"Fr Ophtalmol"},{"key":"335_CR8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/archopht.1980.01020041030004","volume":"98","author":"DB Soll","year":"1980","unstructured":"Soll DB (1980) Evaluation of timolol in chronic openangle glaucoma. Once a day vs twice a day. Arch Ophthalmol 98: 2178\u20132181","journal-title":"Arch Ophthalmol"},{"key":"335_CR9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0161-6420(89)32688-1","volume":"96","author":"DL Epstein","year":"1989","unstructured":"Epstein DL, Krug JH Jr, Hertzmark E, Remis LL, Edelstein DJ (1989) A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 96: 1460\u20131467","journal-title":"Ophthalmology"},{"key":"335_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/jop.1997.13.225","volume":"13","author":"TH Wang","year":"1997","unstructured":"Wang TH, Hung PT, Huang JK, Shih YF (1997) The effect of 0.5 % timolol maleate on the ocular perfusion of ocular hypertensive patients by scanning laser flowmetry. J Ocul Pharmacol Ther 13: 225\u2013233","journal-title":"J Ocul Pharmacol Ther"},{"key":"335_CR11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/bjo.2005.067637","volume":"89","author":"G Fuchsjager-Mayrl","year":"2005","unstructured":"Fuchsjager-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, Weigert G, Polska E, Eichler HG, Vass C, Schmetterer L (2005) Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 89: 1293\u20131297","journal-title":"Br J Ophthalmol"},{"key":"335_CR12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0002-9394(14)70374-5","volume":"122","author":"MT Nicolela","year":"1996","unstructured":"Nicolela MT, Buckley AR, Walman BE, Drance SM (1996) A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol 122: 784\u2013789","journal-title":"Am J Ophthalmol"},{"key":"335_CR13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archopht.1985.01050030075025","volume":"103","author":"FG Berson","year":"1985","unstructured":"Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E (1985) Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Arch Ophthalmol 103: 379\u2013382","journal-title":"Arch Ophthalmol"},{"key":"335_CR14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archopht.1988.01060130668023","volume":"106","author":"FW Boozman 3rd","year":"1988","unstructured":"Boozman FW 3rd, Carriker R, Foerster R, Allen RC, Novack GD, Batoosingh AL (1988) Long-term evaluation of 0.25 % levobunolol and timolol for therapy for elevated intraocular pressure. Arch Ophthalmol 106: 614\u2013618","journal-title":"Arch Ophthalmol"},{"key":"335_CR15","first-page":"420","volume":"28","author":"MB Wax","year":"1987","unstructured":"Wax MB, Molinoff PB (1987) Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. Invest Ophthalmol Vis Sci 28: 420\u2013430","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"335_CR16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0002-9394(14)77274-5","volume":"112","author":"C Messmer","year":"1991","unstructured":"Messmer C, Flammer J, St\u00fcmpfig D (1991) Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 112: 678\u2013681","journal-title":"Am J Ophthalmol"},{"issue":"suppl","key":"335_CR17","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/0039-6257(94)90060-4","volume":"38","author":"HJ Kaiser","year":"1994","unstructured":"Kaiser HJ, Flammer J, St\u00fcmpfig D, Hendrickson P (1994) Longterm visual field follow-up of glaucoma patients treated with beta blockers. Surv Ophthalmol 38(suppl): S156\u2013S159","journal-title":"Surv Ophthalmol"},{"key":"335_CR18","first-page":"317","volume":"28","author":"F Fam\u00e0","year":"1996","unstructured":"Fam\u00e0 F, Santamaria S (1996) Comparison of the ocular effects of three beta-blockers: timolol, carteolol, and betaxolol. Ann Ophthalmology 28: 317\u2013320","journal-title":"Ann Ophthalmology"},{"key":"335_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0039-6257(94)90056-6","volume":"38","author":"RK Hester","year":"1994","unstructured":"Hester RK, Ghen Z, Becker EJ (1994) The direct vascular relaxing action of betaxolol, carteolol, and timolol in porcine long posterior ciliary arteries. Surv Ophthalmol 38: 125\u2013134","journal-title":"Surv Ophthalmol"},{"key":"335_CR20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0002-9394(14)76731-5","volume":"112","author":"JB Serle","year":"1991","unstructured":"Serle JB, Lustgarten JS, Podos SM (1991) A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. Am J Ophthalmol 112: 302\u2013307","journal-title":"Am J Ophthalmol"},{"key":"335_CR21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/bjo.82.8.892","volume":"82","author":"S Wolf","year":"1998","unstructured":"Wolf S, Werner E, Schulte K, Reim M (1998) Acute effect of metipranolol on the retinal circulation. Br J Ophthalmol 82: 892\u2013896","journal-title":"Br J Ophthalmol"},{"key":"335_CR22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0009-9236(97)90138-7","volume":"61","author":"L Schmetterer","year":"1997","unstructured":"Schmetterer L, Strenn K, Findl O, Breiteneder H, Graselli U, Agneter E, Eichler HG, Wolzt M (1997) Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin Pharmacol Ther 61: 583\u2013595","journal-title":"Clin Pharmacol Ther"},{"key":"335_CR23","first-page":"75","volume":"245","author":"K Vercruysse","year":"1992","unstructured":"Vercruysse K, Goethals M, Vandeputte O, Missotten L (1992) A long term clinical trial of carteolol in the management of glaucoma. Belgium Carteolol Study Participants. Bull Soc Belge Ophthalmol 245: 75\u201380","journal-title":"Bull Soc Belge Ophthalmol"},{"key":"335_CR24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0039-6257(87)90116-0","volume":"31","author":"GD Novack","year":"1987","unstructured":"Novack GD (1987) Ophthalmic \u03b2-blockers since timolol. Surv Ophtalmol 31: 307\u2013327","journal-title":"Surv Ophtalmol"},{"key":"335_CR25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00003226-198605010-00012","volume":"5","author":"FT Frauenfelder","year":"1986","unstructured":"Frauenfelder FT, Meyer SM (1986) Corneal complications of ocular medications. Cornea 5: 55\u201359","journal-title":"Cornea"},{"key":"335_CR26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0002-9394(79)90675-5","volume":"88","author":"EM Van Buskirk","year":"1979","unstructured":"Van Buskirk EM (1979) Corneal anesthesia after timolol maleate therapy. Am J Ophthalmol 88: 739\u2013743","journal-title":"Am J Ophthalmol"},{"key":"335_CR27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archopht.1986.01050130056019","volume":"104","author":"RH Stewart","year":"1986","unstructured":"Stewart RH, Kimbrough RL, Ward RL (1986) Betaxolol vs timolol. A six-month double-blind comparison. Arch Ophthalmol 104: 46\u201348","journal-title":"Arch Ophthalmol"},{"key":"335_CR28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bjo.75.9.519","volume":"75","author":"T Akingbehin","year":"1991","unstructured":"Akingbehin T, Villada JR (1991) Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 75: 519\u2013523","journal-title":"Br J Ophthalmol"},{"key":"335_CR29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0002-9394(14)70432-5","volume":"121","author":"K Dickstein","year":"1996","unstructured":"Dickstein K, Aarsland T (1996) Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men. Am J Ophthalmol 121: 367\u2013371","journal-title":"Am J Ophthalmol"},{"key":"335_CR30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00061198-199912000-00009","volume":"8","author":"JD Bartlett","year":"1999","unstructured":"Bartlett JD, Olivier M, Richardson T, Whitaker R Jr, Pensyl D, Wilson MR (1999) Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. J Glaucoma 8: 388\u2013395","journal-title":"J Glaucoma"},{"key":"335_CR31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0161-6420(80)35215-9","volume":"87","author":"EM Van Buskirk","year":"1980","unstructured":"Van Buskirk EM (1980) Adverse reactions from timolol administration. Ophthalmology 87: 447\u2013450","journal-title":"Ophthalmology"},{"key":"335_CR32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/bjo.62.5.302","volume":"62","author":"I Grierson","year":"1978","unstructured":"Grierson, I, Lee, W, Abraham, S (1978) Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol 62: 302\u2013313","journal-title":"Br J Ophthalmol"},{"key":"335_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9394(64)92029-X","volume":"57","author":"AE Krill","year":"1964","unstructured":"Krill AE, Newell FW (1964) Effects of pilocarpine on ocular tension dynamics. Am J Ophthalmol 57: 34\u201341","journal-title":"Am J Ophthalmol"},{"key":"335_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archopht.1970.00990040607008","volume":"84","author":"LS Harris","year":"1970","unstructured":"Harris LS, Galin MA (1970) Dose response analysis of pilocarpine-induced ocular hypotension. Arch Ophthalmol 84: 605\u2013608","journal-title":"Arch Ophthalmol"},{"key":"335_CR35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0002-9394(71)91689-8","volume":"72","author":"LS Harris","year":"1971","unstructured":"Harris LS, Galin MA (1971) Effect of ocular pigmentation on hypotensive response to pilocarpine. Am J Ophthalmol 72: 923\u2013925","journal-title":"Am J Ophthalmol"},{"key":"335_CR36","first-page":"784","volume":"20","author":"HS Chen","year":"1989","unstructured":"Chen HS, Steinmann WC, Spaeth GL (1989) The effect of chronic miotic therapy on the results of posterior chamber intraocular lens implantation and trabeculectomy in patients with glaucoma. Ophthalmic Surg 20: 784\u2013788","journal-title":"Ophthalmic Surg"},{"key":"335_CR37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0161-6420(81)35072-6","volume":"88","author":"TJ Zimmerman","year":"1981","unstructured":"Zimmerman TJ (1981) Pilocarpine. Ophthalmology 88: 85\u201388","journal-title":"Ophthalmology"},{"key":"335_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0161-6420(82)34866-6","volume":"89","author":"TJ Zimmerman","year":"1982","unstructured":"Zimmerman TJ, Wheeler TM (1982) Miotics: side effects and ways to avoid them. Ophthalmology 89: 76\u201380","journal-title":"Ophthalmology"},{"key":"335_CR39","first-page":"416","volume":"33","author":"M Mori","year":"1992","unstructured":"Mori M, Araie M, Sakurai M, Oshika T (1992) Effects of pilocarpine and tropicamide on blood-aqueous barrier permeability in man. Invest Ophthalmol Vis Sci 33: 416\u2013423","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"335_CR40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0039-6257(91)90053-I","volume":"35","author":"MF Kraushar","year":"1991","unstructured":"Kraushar MF, Steinberg JA (1991) Miotics and retinal detachment: upgrading the community standard. Surv Ophthalmol 35: 311\u2013316","journal-title":"Surv Ophthalmol"},{"key":"335_CR41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archopht.1982.01030030264005","volume":"100","author":"PT Hung","year":"1982","unstructured":"Hung PT, Hsieh JW, Chiou GC (1982) Ocular hypotensive effects of N-demethylated carbachol on open angle glaucoma. Arch Ophthalmol 100: 262\u2013264","journal-title":"Arch Ophthalmol"},{"key":"335_CR42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0161-6420(88)33038-1","volume":"95","author":"NZ Gharagozloo","year":"1988","unstructured":"Gharagozloo NZ, Relf SJ, Brubaker RF (1988) Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 95: 1217\u20131220","journal-title":"Ophthalmology"},{"key":"335_CR43","first-page":"298","volume":"6","author":"RL Gross","year":"1997","unstructured":"Gross RL, Pinyero A, Orengo-Nania S (1997) Clinical experience with apraclonidine 0.5 %. J Glaucoma 6: 298\u2013302","journal-title":"J Glaucoma"},{"key":"335_CR44","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0161-6420(13)31818-1","volume":"100","author":"S Nagasubramanian","year":"1993","unstructured":"Nagasubramanian S, Hitchings RA, Demailly P, Chuniaud M, Pannarale MR, Pecori-Giraldi J, Stodtmeister R, Parsons DG (1993) Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology 100: 1318\u20131323","journal-title":"Ophthalmology"},{"key":"335_CR45","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archopht.1988.01060140225029","volume":"106","author":"HD Jampel","year":"1988","unstructured":"Jampel HD, Robin AL, Quigley HA, Pollack IP (1988) Apraclonidine. A one-week dose-response study. Arch Ophthalmol 106: 1069\u20131073","journal-title":"Arch Ophthalmol"},{"key":"335_CR46","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","volume":"105","author":"RP LeBlanc","year":"1998","unstructured":"LeBlanc RP (1998) Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2 % and timolol 0.5 % given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 105: 1960\u20131967","journal-title":"Ophthalmology"},{"key":"335_CR47","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0149-2918(01)80089-8","volume":"23","author":"LB Cantor","year":"2001","unstructured":"Cantor LB, Hoop J, Katz LJ, Flartey K (2001) Alphagan\/ Betaxolol Clinical Success Study Group. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2 % and betaxolol 0.25 % suspension in patients with elevated intraocular pressure. Clin Ther 23: 1032\u20131039","journal-title":"Clin Ther"},{"key":"335_CR48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(00)00389-5","volume":"129","author":"AM Carlsson","year":"2000","unstructured":"Carlsson AM, Chauhan BC, Lee AA, LeBlanc RP (2000) The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol 129: 297\u2013301","journal-title":"Am J Ophthalmol"},{"key":"335_CR49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0014-4886(03)00298-X","volume":"184","author":"M Aviles-Trigueros","year":"2003","unstructured":"Aviles-Trigueros M, Mayor-Torroglosa S, Garcia-Aviles A, Lafuente MP, Rodriguez ME, Miralles de Imperial J, Villegas-Perez MP, Vidal-Sanz M (2003)Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp Neurol 184: 767\u2013777","journal-title":"Exp Neurol"},{"key":"335_CR50","first-page":"670","volume":"264","author":"WF Brechue","year":"1993","unstructured":"Brechue WF, Maren TH (1993) Carbonic anhydrase inhibitory activity and ocular pharmacology of organic sulfamates. J Pharmacol Exp Ther 264: 670\u2013675","journal-title":"J Pharmacol Exp Ther"},{"key":"335_CR51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archopht.1995.01100080061030","volume":"113","author":"E Strahlman","year":"1995","unstructured":"Strahlman E, Tipping R, Vogel R (1995) A doublemasked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 113: 1009\u20131016","journal-title":"Arch Ophthalmol"},{"key":"335_CR52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0161-6420(91)32295-4","volume":"98","author":"EA Lippa","year":"1991","unstructured":"Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, Epstein DL, Shaw B, Holder DJ, Deasy DA (1991) MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 98: 308\u2013312","journal-title":"Ophthalmology"},{"key":"335_CR53","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0161-6420(98)98043-5","volume":"105","author":"BD Vanlandingham","year":"1998","unstructured":"Vanlandingham BD, Maus TL, Brubaker RF (1998) The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep. Ophthalmology 105: 1537\u20131540","journal-title":"Ophthalmology"},{"key":"335_CR54","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/bjo.2005.067637","volume":"89","author":"G Fuchsjager-Mayrl","year":"2005","unstructured":"Fuchsjager-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, Weigert G, Polska E, Eichler HG, Vass C, Schmetterer L (2005) Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 89: 1293\u20131297","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 2","key":"335_CR55","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/S0039-6257(99)00110-1","volume":"44","author":"LH Silver","year":"2000","unstructured":"Silver LH (2000) Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Surv Ophthalmol 44(Suppl 2): S147\u2013S153","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 2","key":"335_CR56","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S0039-6257(99)00106-X","volume":"44","author":"D Shin","year":"2000","unstructured":"Shin D (2000) Adjunctive therapy with brinzolamide 1 % ophthalmic suspension (Azopt) in patients with openangle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 44(Suppl 2): S163\u2013S168","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 2","key":"335_CR57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0039-6257(97)80015-X","volume":"41","author":"T Yamamoto","year":"1997","unstructured":"Yamamoto T, Kitazawa Y, Azuma I, Masuda K (1997) Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone). Surv Ophthalmol 41(Suppl 2): 99\u2013103","journal-title":"Surv Ophthalmol"},{"key":"335_CR58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00061198-200312000-00004","volume":"12","author":"CB Camras","year":"2003","unstructured":"Camras CB, Hedman K, US Latanoprost Study Group (2003) Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 12: 466\u2013469","journal-title":"J Glaucoma"},{"key":"335_CR59","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archopht.117.6.794","volume":"117","author":"T Sagara","year":"1999","unstructured":"Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN (1999) Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 117: 794\u2013801","journal-title":"Arch Ophthalmol"},{"key":"335_CR60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(98)91372-0","volume":"105","author":"PG Watson","year":"1998","unstructured":"Watson PG (1998) Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 105: 82\u201387","journal-title":"Ophthalmology"},{"key":"335_CR61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/archopht.1996.01100130264005","volume":"114","author":"P Racz","year":"1996","unstructured":"Racz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ (1996) Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 114: 268\u2013273","journal-title":"Arch Ophthalmol"},{"key":"335_CR62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(99)90115-X","volume":"106","author":"L Mastropasqua","year":"1999","unstructured":"Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE (1999) A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 106: 550\u2013555","journal-title":"Ophthalmology"},{"key":"335_CR63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-9394(98)00019-1","volume":"125","author":"SM Drance","year":"1998","unstructured":"Drance SM, Crichton A, Mills RP (1998) Comparison of the effect of latanoprost 0.005 % and timolol 0.5 % on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol 125: 585\u2013592","journal-title":"Am J Ophthalmol"},{"key":"335_CR64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/108076801753266785","volume":"17","author":"Y Tamaki","year":"2001","unstructured":"Tamaki Y, Nagahara M, Araie M, Tomita K, Sandoh S, Tomidokoro A (2001) Topical latanoprost and optic nerve head and retinal circulation in humans. J Ocul Pharmacol Ther 17: 403\u2013411","journal-title":"J Ocul Pharmacol Ther"},{"key":"335_CR65","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0161-6420(99)00528-X","volume":"106","author":"SE Moroi","year":"1999","unstructured":"Moroi SE, Gottfredsdottir MS, Schteingart MT, Elner SG, Lee CM, Schertzer RM, Abrams GW, Johnson MW (1999) Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 106: 1024\u20131029","journal-title":"Ophthalmology"},{"key":"335_CR66","first-page":"282","volume":"41","author":"AC Kothe","year":"2000","unstructured":"Kothe AC, Ripp KM, Sharma V (2000) IOP lowering efficacy and safety of travoprost BID vs. concomitantly dosed travoprost and brimonidine BID vs. placebo BID in patients with open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41: 282","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"335_CR67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00019053-200624030-00010","volume":"24","author":"GL Plosker","year":"2006","unstructured":"Plosker GL, Keam SJ (2006) Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 24: 297\u2013314","journal-title":"Pharmacoeconomics"},{"key":"335_CR68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2003-38167","volume":"220","author":"R Allemann","year":"2003","unstructured":"Allemann R, Flammer J, Haefliger IO (2003) Vasoactive properties of bimatoprost in isolated porcine ciliary arteries. Klin Monatsbl Augenheilkd 220: 161\u2013164","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"335_CR69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0021-5155(97)00128-7","volume":"42","author":"JB Serle","year":"1998","unstructured":"Serle JB, Podos SM, Kitazawa Y, Wang RF (1998) A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol 42: 95\u2013100","journal-title":"Jpn J Ophthalmol"},{"key":"335_CR70","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/archopht.120.3.348","volume":"120","author":"E Polska","year":"2002","unstructured":"Polska E, Doelemeyer A, Luksch A, Ehrlich P, Kaehler N, Percicot CL, Lambrou GN, Schmetterer L (2002) Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol 120: 348\u2013352","journal-title":"Arch Ophthalmol"},{"key":"335_CR71","first-page":"39","volume":"104","author":"Y Makimoto","year":"2000","unstructured":"Makimoto Y, Sugiyama T, Kojima S, Azuma I (2000) Long-term effect of topically applied isopropyl unoprostone on microcirculation in the choroid-retina. Nippon Ganka Gakkai Zasshi 104: 39\u201343","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"335_CR72","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0161-6420(98)91045-4","volume":"105","author":"K Strohmaier","year":"1998","unstructured":"Strohmaier K, Snyder E, DuBiner H, Adamsons I (1998) The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 105: 1936\u20131944","journal-title":"Ophthalmology"},{"key":"335_CR73","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/S0161-6420(98)91047-8","volume":"105","author":"CM Clineschmidt","year":"1998","unstructured":"Clineschmidt CM, Williams RD, Snyder E, Adamsons IA (1998) A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamidetimolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group Ophthalmology 105: 1952\u20131959","journal-title":"Ophthalmology"},{"key":"335_CR74","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.clinthera.2004.10.009","volume":"26","author":"K Olander","year":"2004","unstructured":"Olander K, Zimmerman TJ, Downes N, Schoenfelder J; Xalacom\/Latanoprost Study (2004) Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Group Clin Ther 26:1619\u20131629","journal-title":"Group Clin Ther"},{"key":"335_CR75","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2005.02.058","volume":"140","author":"JS Schuman","year":"2005","unstructured":"Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT, Sullivan EK, Landry TA, Bergamini MV, Robertson SM (2005) Efficacy and safety of a fixed combination of travoprost 0.004 %\/timolol 0.5 % ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 140: 242\u2013250","journal-title":"Am J Ophthalmol"},{"key":"335_CR76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jop.2005.21.337","volume":"21","author":"ER Craven","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group (2005) Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-monthrandomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 21: 337\u2013348","journal-title":"J Ocul Pharmacol Ther"},{"key":"335_CR77","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archopht.1982.01030030137016","volume":"100","author":"HA Quigley","year":"1982","unstructured":"Quigley HA, Addicks EM, Green WR (1982) Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defects in glaucoma, ischemic optic neuropathy, papilledema, and toxic optic neuropathy. Arch Ophthalmol 100: 135\u2013146","journal-title":"Arch Ophthalmol"},{"key":"335_CR78","first-page":"159","volume":"38","author":"SC Yui","year":"1997","unstructured":"Yui SC, Jollimore CA, Tatton N, Kelley MEM (1997) Deprenyl increases cell survival and decreases apoptosis in rat retinal cultures following trophic withdrawal. Invest Ophthalmol Vis Sci 38: 159, Abstract 788","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-006-0335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-006-0335-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-006-0335-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:03:40Z","timestamp":1559145820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-006-0335-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":78,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s10354-006-0335-0","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}